While this compound inhibits mitochondrial carnitine palmitoyltransferase-1, and not HES1, perhexiline exhibited antitumor responses in vivo in a preclinical model of T-ALL and showed no significant adverse effects on the hematopoietic system [150]. Here, HES1 is linked to acute lymphoblastic leukemia.